- Home
- REFI vs DCTH Comparison
REFI vs DCTH Comparison
Compare REFI & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- DCTH
- Stock Information
- Founded
- REFI 2021
- DCTH 1988
- Country
- REFI United States
- DCTH United States
- Employees
- REFI N/A
- DCTH N/A
- Industry
- REFI Real Estate Investment Trusts
- DCTH Medical/Dental Instruments
- Sector
- REFI Real Estate
- DCTH Health Care
- Exchange
- REFI Nasdaq
- DCTH Nasdaq
- Market Cap
- REFI 306.1M
- DCTH 352.0M
- IPO Year
- REFI 2021
- DCTH N/A
- Fundamental
- Price
- REFI $16.21
- DCTH $11.97
- Analyst Decision
- REFI Strong Buy
- DCTH Strong Buy
- Analyst Count
- REFI 3
- DCTH 4
- Target Price
- REFI $20.00
- DCTH $21.50
- AVG Volume (30 Days)
- REFI 121.4K
- DCTH 345.3K
- Earning Date
- REFI 11-07-2024
- DCTH 11-08-2024
- Dividend Yield
- REFI 11.60%
- DCTH N/A
- EPS Growth
- REFI N/A
- DCTH N/A
- EPS
- REFI 2.00
- DCTH N/A
- Revenue
- REFI $56,860,278.00
- DCTH $22,644,000.00
- Revenue This Year
- REFI N/A
- DCTH $1,605.13
- Revenue Next Year
- REFI $4.27
- DCTH $111.67
- P/E Ratio
- REFI $8.11
- DCTH N/A
- Revenue Growth
- REFI 6.49
- DCTH 945.91
- 52 Week Low
- REFI $14.82
- DCTH $3.70
- 52 Week High
- REFI $16.75
- DCTH $13.30
- Technical
- Relative Strength Index (RSI)
- REFI 58.66
- DCTH 57.26
- Support Level
- REFI $15.69
- DCTH $10.75
- Resistance Level
- REFI $16.24
- DCTH $13.30
- Average True Range (ATR)
- REFI 0.20
- DCTH 0.75
- MACD
- REFI -0.02
- DCTH -0.08
- Stochastic Oscillator
- REFI 90.32
- DCTH 47.82
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.